Colchicoside
Based on 1 Customer Validation
Colchicoside is a monoglycosylated colchicine alkaloid glycoside with anti-leishmanial activity. Colchicoside can be obtained by specific glycosylation of Colchicine (HY-16569) by Astragalus vesicarius plant suspension cells, and is also found in Gloriosa superba seeds. Colchicoside can serve as a precursor for the synthesis of Thiocolchicoside (HY-N0301). Colchicoside can be used in research related to anti-leishmanial infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.37%
- No. CAS: 477-29-2
- Fòrmula: C27H33NO11
- Peso molecular:547.55
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Parasite
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
Leishmania 0.22 μg/mL (IC50) |
In Vitro
Colchicoside accumulates intracellularly in Astragalus vesicarius suspension cells after 14 days of biotransformation with Colchicine (HY-16569) as substrate[1].
Colchicoside is prepared by chemical semi-synthesis from 3-Demethylcolchicine (HY-W021267) and α-acetobromoglucose[2].
Colchicoside exhibits potent in vitro antileishmanial activity against Leishmania major promastigotes (IC50 = 0.22 µg/mL) and ex vivo activity against intracellular amastigotes (IC50 = 4.03 µg/mL, selectivity index = 18.33), along with iron-chelating and anti-inflammatory effects[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 477-29-2
-
Appearance Solid
-
Peso molecular 547.55
-
Fòrmula C27H33NO11
-
Color Light yellow to yellow
-
SMILES
CC(N[C@H](C1=C2)CCC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)=C(OC)C(OC)=C3C1=CC=C(OC)C2=O)=O
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
DMSO : ≥ 30 mg/mL (54.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
-
Ficha de datos (290 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8263 mL | 9.1316 mL | 18.2632 mL | 45.6579 mL |
| 5 mM | 0.3653 mL | 1.8263 mL | 3.6526 mL | 9.1316 mL | |
| 10 mM | 0.1826 mL | 0.9132 mL | 1.8263 mL | 4.5658 mL | |
| 15 mM | 0.1218 mL | 0.6088 mL | 1.2175 mL | 3.0439 mL | |
| 20 mM | 0.0913 mL | 0.4566 mL | 0.9132 mL | 2.2829 mL | |
| 25 mM | 0.0731 mL | 0.3653 mL | 0.7305 mL | 1.8263 mL | |
| 30 mM | 0.0609 mL | 0.3044 mL | 0.6088 mL | 1.5219 mL | |
| 40 mM | 0.0457 mL | 0.2283 mL | 0.4566 mL | 1.1414 mL | |
| 50 mM | 0.0365 mL | 0.1826 mL | 0.3653 mL | 0.9132 mL |
Colchicoside Related Classifications
HY-131300 Related Classifications
Powered by Bioz